Trial Profile

A Phase I double-blind, placebo-controlled, single-ascending dose study of SBT-272 in healthy volunteers

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 17 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevemipretide (Primary)
Indications Amyotrophic lateral sclerosis; Frontotemporal dementia; Multiple system atrophy; Parkinson's disease; Stroke
Focus Adverse reactions; First in man
Sponsors Mighty Therapeutics

16 Jun 2026 According to Stealth BioTherapeutics media release, Stealth BioTherapeutics is now called Mighty Therapeutics.
27 Apr 2026 According to a Stealth BioTherapeutics media release, Preliminary results from both the single ascending dose (SAD) and multiple ascending dose (MAD) parts of the trial will be presented at the 2026 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, to be held on May 3-7 in Denver, Colo.
27 Apr 2026 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com